INTRA-ARTERIAL CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER: A LITERATURE REVIEW.

K Cherchenko, Y Ostapenko, V Patsko, O Vlasenko, M Vinohradova, A Rudskoi, K Valikhnovska, A Lukashenko
{"title":"INTRA-ARTERIAL CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER: A LITERATURE REVIEW.","authors":"K Cherchenko, Y Ostapenko, V Patsko, O Vlasenko, M Vinohradova, A Rudskoi, K Valikhnovska, A Lukashenko","doi":"10.15407/exp-oncology.2025.04.421","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic cancer is an extremely aggressive malignancy with a 5-year survival rate among all stages of about 7%. Treatment options for unresectable forms are limited to fluoropyrimidine- and gemcitabine-containing regimens, and starting from the 3rd line, international guidelines do not provide clear recommendations because of the poor clinical condition of patients and the low efficacy of the consecutive lines. The arterial infusion is a promising method of treatment for locally advanced or liver-only metastatic disease, providing a higher local concentration with the same or lower systemic toxicity. The most often used intra-arterial regimens are those based on 5-fluorouracil and gemcitabine. This method was found to be superior in overall survival, response rate, and control of local symptoms compared to control groups treated with systemic chemotherapy. The approach has a good safety profile and is well tolerated. The method is promising for patients with an adequate performance status, who have run out of other potential regimens, in cases without distant metastases or liver-only metastatic disease, and for upcoming clinical trials or studies.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 4","pages":"421-432"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/exp-oncology.2025.04.421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pancreatic cancer is an extremely aggressive malignancy with a 5-year survival rate among all stages of about 7%. Treatment options for unresectable forms are limited to fluoropyrimidine- and gemcitabine-containing regimens, and starting from the 3rd line, international guidelines do not provide clear recommendations because of the poor clinical condition of patients and the low efficacy of the consecutive lines. The arterial infusion is a promising method of treatment for locally advanced or liver-only metastatic disease, providing a higher local concentration with the same or lower systemic toxicity. The most often used intra-arterial regimens are those based on 5-fluorouracil and gemcitabine. This method was found to be superior in overall survival, response rate, and control of local symptoms compared to control groups treated with systemic chemotherapy. The approach has a good safety profile and is well tolerated. The method is promising for patients with an adequate performance status, who have run out of other potential regimens, in cases without distant metastases or liver-only metastatic disease, and for upcoming clinical trials or studies.

晚期胰腺癌动脉内化疗的文献综述。
胰腺癌是一种极具侵袭性的恶性肿瘤,所有分期的5年生存率约为7%。不可切除形式的治疗选择仅限于含氟嘧啶和吉西他滨的方案,从第3条线开始,由于患者临床状况不佳和连续线的疗效低,国际指南没有提供明确的建议。动脉输注是治疗局部晚期或仅肝脏转移性疾病的一种很有前途的方法,提供较高的局部浓度和相同或更低的全身毒性。最常用的动脉内治疗方案是以5-氟尿嘧啶和吉西他滨为基础的。与接受全身化疗的对照组相比,该方法在总生存率、缓解率和局部症状控制方面均优于对照组。该方法具有良好的安全性和耐受性。该方法对于那些已经用尽其他潜在治疗方案、没有远处转移或仅肝脏转移疾病的患者以及即将进行的临床试验或研究来说是有希望的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书